Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Open Access
- 30 October 2020
- Vol. 8 (4), 632
- https://doi.org/10.3390/vaccines8040632
Abstract
Immune check-point inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and their apparently random effect in terms of efficacy and toxicity. This marked pharmacodynamics variability in patients calls for reconsidering to what extent approved dosing used in clinical practice are optimal or whether they should require efforts for customization in outlier patients. To better understand whether or not dosing could be an actionable item in oncology, in this review, preclinical and clinical development of immune checkpoint inhibitors are described, particularly from the angle of dose finding studies. Other issues in connection with dosing issues are developed, such as the flat dosing alternative, the putative role therapeutic drug monitoring could play, the rise of combinatorial strategies, and pharmaco-economic aspects.This publication has 132 references indexed in Scilit:
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer TherapiesJournal of Clinical Oncology, 2012
- Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsBritish Journal of Cancer, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- A Guide to Rational Dosing of Monoclonal AntibodiesClinical Pharmacokinetics, 2012
- TGN1412: From Discovery to DisasterJournal of Young Pharmacists, 2010
- Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized miceProceedings of the National Academy of Sciences of the United States of America, 2009
- Matrix metalloproteinases at cancer tumor–host interfaceSeminars in Cell & Developmental Biology, 2008
- Flat-Fixed Dosing Versus Body Surface Area–Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?The Oncologist, 2007
- Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti–CTLA-4 antibodiesBlood, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004